المؤلفون: A. G. Romanovskikh, A. I. Sinopal’nikov, Yu. G. Belotserkovskaya, I. P. Smirnov, А. Г. Романовских, А. И. Синопальников, Ю. Г. Белоцерковская, И. П. Смирнов

المساهمون: This publication is supported by Boehringer Ingelheim LLC, Статья опубликована при финансовой поддержке ООО Берингер Ингельхейм

المصدر: PULMONOLOGIYA; Том 31, № 4 (2021); 511-516 ; Пульмонология; Том 31, № 4 (2021); 511-516 ; 2541-9617 ; 0869-0189

مصطلحات موضوعية: комбинации тиотропия бромид / олодатерол. Конфликт интересов, cardiovascular diseases, pharmacotherapy of COPD, tiotropium/olodaterol, сердечно-сосудистые заболевания, фармакотерапия хронической обструктивной болезни легких

وصف الملف: application/pdf

العلاقة: https://journal.pulmonology.ru/pulm/article/view/2414/1865Test; Российское респираторное общество. Хроническая обструктивная болезнь легких: Федеральные клинические рекомендации. 2018. Доступно на: https://spulmo.ru/upload/federal_klinicheskie_rekomendaciy_hobl.pdfTest [Дата обращения: 05.01.21].; Vanfleteren L.E.G., Spruit M.A., Groenen M. et al. Clusters of comorbidities based on validated objective measurements and systemic inflammation in patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2013; 187 (7): 728–735. DOI:10.1164/rccm.201209-1665OC.; Barnes P.J., Celli B.R. Systemic manifestations and comorbidities of COPD. Eur. Respir. J. 2009; 33 (5): 1165–1185. DOI:10.1183/09031936.00128008.; Antonelli Incalzi R., Fuso L., De Rosa M. et al. Co-morbidity contributes to predict mortality of patients with chronic obstructive pulmonary disease. Eur. Respir. J. 1997; 10 (12): 2794–2800. DOI:10.1183/09031936.97.10122794.; Morgan A.D., Zakeri R., Quint J.K. Defining the relationship between COPD and CVD: what are the implications for clinical practice? Ther. Adv. Respir. Dis. 2018; 12: 1753465817750524. DOI:10.1177/1753465817750524.; Curkendall S.M., Lanes S., de Luise C. et al. Chronic obstructive pulmonary disease severity and cardiovascular outcomes. Eur. J. Epidemiol. 2006; 21 (11): 803–813. DOI:10.1007/s10654-006-9066-1.; Mannino D.M., Thorn D., Swensen A., Holguin F. Prevalence and outcomes of diabetes, hypertension and cardiovascular disease in COPD. Eur. Respir. J. 2008; 32 (4): 962–969. DOI:10.1183/09031936.00012408.; Almagro P., López F., Cabrera F.J. et al. [Comorbidities in patients hospitalized due to chronic obstructive pulmonary disease. A comparative analysis of the ECCO and ESMI studies]. Rev. Clin. Esp. 2012; 212 (6): 281–286. DOI:10.1016/j.rce.2012.02.014 (in Spanish).; Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. 2020 Report. Available at: https://goldcopd.org/wp-content/uploads/2019/11/GOLD-2020-REPORTver1.0wms.pdfTest [Available at: June 28, 2021].; Hohlfeld J.M., Vogel-Claussen J., Biller H. et al. Effect of lung deflation with indacaterol plus glycopyrronium on ventricular filling in patients with hyperinflation and COPD (CLAIM): a double-blind, randomised, crossover, placebo-controlled, single-centre trial. Lancet Respir. Med. 2018; 6 (5): 368–378. DOI:10.1016/S2213-2600(18)30054-7.; Rogliani P., Matera M.G., Ritondo B.L. et al. Efficacy and cardiovascular safety profile of dual bronchodilation therapy in chronic obstructive pulmonary disease: A bidimensional comparative analysis across fixed-dose combinations. Pulm. Pharmacol. Ther. 2019; 59: 101841. DOI:10.1016/j.pupt.2019.101841.; Calverley P.M.A., Anzueto A.R., Carter K. et al. Tiotropium and olodaterol in the prevention of chronic obstructive pulmonary disease exacerbations (DYNAGITO): a double-blind, randomised, parallel-group, active-controlled trial. Lancet Respir. Med. 2018; 6 (5): 337–344. DOI:10.1016/S2213-2600(18)30102-4.; Andreas S., McGarvey L., Bothner U. et al. Absence of adverse effects of tiotropium/olodaterol compared with the monocomponents on long-term heart rate and blood pressure in patients with moderate-to-very-severe COPD. Int. J. Chron. Obstruct. Pulmon Dis. 2020; 15: 1935–1944. DOI:10.2147/COPD.S246348.; Ferguson G.T., Buhl R., Bothner U. et al. Safety of tiotropium/ olodaterol in chronic obstructive pulmonary disease: pooled analysis of three large, 52-week, randomized clinical trials. Respir. Med. 2018; 143: 67–73. DOI:10.1016/j.rmed.2018.08.012.; Valipour A., Avdeev S., Barczyk A. et al. Therapeutic success of tiotropium/olodaterol, measured using the Clinical COPD Questionnaire (CCQ), in routine clinical practice: A multinational non-interventional study. Int. J. Chron. Obstruct. Pulmon. Dis. 2021; 16: 615–628. DOI:10.2147/COPD.S291920.; https://journal.pulmonology.ru/pulm/article/view/2414Test

الإتاحة: https://doi.org/10.18093/0869-0189-2021-31-4-511-516Test
https://doi.org/10.1164/rccm.201209-1665OCTest
https://doi.org/10.1183/09031936.00128008Test
https://doi.org/10.1183/09031936.97.10122794Test
https://doi.org/10.1007/s10654-006-9066-1Test
https://doi.org/10.1183/09031936.00012408Test
https://doi.org/10.1016/j.rce.2012.02.014Test
https://doi.org/10.1016/S2213-2600Test(18)30054-7
https://doi.org/10.1016/j.pupt.2019.101841Test
https://doi.org/10.1016/S2213-2600Test(18)30102-4

المؤلفون: Ekaterina S. Gladysheva, Robert L. Owens, Atul Malhotra

المصدر: International Journal of COPD, Vol 2010, Iss default, Pp 153-164 (2010)
International Journal of Chronic Obstructive Pulmonary Disease

مصطلحات موضوعية: Adult, Male, Spirometry, medicine.medical_specialty, medicine.medical_treatment, pharmacotherapy in COPD, Review, Disease, Pulmonary function testing, Pulmonary Disease, Chronic Obstructive, Pharmacotherapy, Drug Therapy, Intervention (counseling), COPD, Humans, Medicine, Intensive care medicine, Lung, anti-inflammatory, Aged, lcsh:RC705-779, medicine.diagnostic_test, business.industry, pulmonary function, General Medicine, lcsh:Diseases of the respiratory system, Middle Aged, medicine.disease, Respiratory Function Tests, respiratory tract diseases, Clinical trial, emphysema, beta-agonist, Smoking cessation, Female, business

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::56b99e082ca35ab5619b65880acbaba7Test
http://www.dovepress.com/influencing-the-decline-of-lung-function-inTest-copd-use-of-pharmacotherap-a4448

المؤلفون: Gladysheva, Ekaterina S., Malhotra, Atul, Owens, Robert Llewellyn

مصطلحات موضوعية: COPD, emphysema, pulmonary function, beta-agonist, anti-inflammatory, pharmacotherapy in COPD

وصف الملف: application/pdf

العلاقة: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2898088/pdfTest/; http://www.dovepress.com/articles.php?article_id=4448Test; International Journal of Chronic Obstructive Pulmonary Disease; Gladysheva, Ekaterina S, Atul Malhotra, and Robert L Owens. 2010. Influencing the decline of lung function in COPD: Use of pharmacotherapy. International Journal of Chronic Obstructive Pulmonary Disease 5:153-164.; http://nrs.harvard.edu/urn-3:HUL.InstRepos:10230118Test

الإتاحة: https://doi.org/10.2147Test/COPD.S4577
http://nrs.harvard.edu/urn-3:HUL.InstRepos:10230118Test